Zydus Cadila receives USFDA approval to market Solifenacin Succinate tablets

Zydus Cadila, a leading pharmaceutical company, announced on Tuesday that it has received final approval from United States Food & Drug Administration (USFDA) for marketing Solifenacin Succinate tablets. Reacting to this news, its share rose more than one per cent on BSE.

The drug company will market Solifenacin Succinate tablets (Vesicare tablets) in the strengths of 5 mg and 10 mg, which is used in the treatment of overactive bladder syndrome. Solifenacin Succinate is a symptomatic treatment of urge incontinence and increased urinary frequency as well as urgency as may occur in patients with the aforementioned syndrome.

The tablets are said to be manufactured at the company’s formulation manufacturing facility at SEZ Ahemdabad.

The global pharmaceutical company, Zydus Cadila, discovers, develops, manufactures & markets a broad range of healthcare therapies. The group currently has 309 approvals along with 390 abbreviated new drug applications (ANDAs).

At 1.08 pm today, the share of Cadila Healthcare was trading 1.09 per cent up at Rs 427.7 on BSE. The share gave 67 per cent returns on a YTD basis. It has a 52-week high of Rs 447.95 and a 52-week low of Rs 212.7 on BSE.